Drug · CHEMBL443

SULFAMETHOXAZOLE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. SULFAMETHOXAZOLE. Drugs and targets, record CHEMBL443. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL443

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: SULFAMETHOXAZOLE; ChEMBL
ChEMBL ID: CHEMBL443; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Gantanol, Gantanol-ds, Sinomin, Sulfamethoxazole component of azo gantanol, Sulfamethoxazole component of bactrim, Sulfamethoxazole component of bactrim ds, Sulfamethoxazole component of bactrim pediatric, Sulfamethoxazole component of co-trimethoxazole, Sulfamethoxazole component of cotrim, Sulfamethoxazole component of cotrim d.s., Sulfamethoxazole component of septra, Sulfamethoxazole component of sulfamethoprim, Sulfamethoxazole component of sulfatrim, Sulfamethoxazole component of sulmeprim, Sulfamethoxazole component of uroplus, Suphamethoxazole, Urobak; ChEMBL
Other names: Acetylsulfamethoxazole, NSC-147832, RO 4-2130, RO-4-2130, STX-608, Sulfamethoxazole sodium, Sulfamethoxazolum, Sulfametoxazol, Sulphamethoxazole; ChEMBL
DrugBank: DB01015; DrugBank
InChIKey: JLKIGFTWXXRPMT-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 5 of its 28 diseases, from ATC, DailyMed, FDA and TTD; Open Targets

Targets0

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

None in this release.

Diseases28

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
pneumocystosis	Approval	DailyMed	72	7	https://conductscience.org/library/drugs?q=MONDO_0019121
Lymphoma, AIDS-Related	Phase 2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=EFO_1001365
cellulitis	Phase 2/3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0005230
infection	Approval	DailyMed	104	1	https://conductscience.org/library/drugs?q=EFO_0000544
AIDS	Phase 3	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0012268
Acute bronchitis	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=HP_0012388
Cutaneous abscess	Phase 2/3	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=HP_0031292
Hypotonia - cystinuria syndrome	Phase 2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=Orphanet_163690
Respiratory tract infection	Phase 2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=HP_0011947
Tachypnea	Phase 3	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=HP_0002789

1 to 10 of 28Source Open Targets

See all 28 diseases

Trials54

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 5 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 11 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00729937	Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"	Phase 2/3	2,265	2014-05-28	trimethoprim-sulfamethoxazole	A combination that names it	ClinicalTrials.gov
NCT00730028	Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus	Phase 2	1,310	2016-03-17	trimethoprim-sulfamethoxazole	A combination that names it	ClinicalTrials.gov
NCT00405704	Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)	Phase 3	607	2015-04-16	trimethoprim-sulfamethoxazole	A combination that names it	ClinicalTrials.gov
NCT01659866	Antibiotic Prophylaxis for Transrectal Prostate Biopsy	Phase 4	563	2019-06-25	trimethoprim-sulfamethoxazole	A combination that names it	ClinicalTrials.gov
NCT02759120	CleanUP IPF for the Pulmonary Trials Cooperative	Phase 3	513	2021-03-03	sulfamethoxazole	Its name	ClinicalTrials.gov
NCT00061945	Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia	Phase 1/2	302	2014-04-16	trimethoprim-sulfamethoxazole	A combination that names it	ClinicalTrials.gov
NCT00679302	Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management	Phase 4	161	2014-04-29	trimethoprim-sulfamethoxazole	A combination that names it	ClinicalTrials.gov
NCT00141037	Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation	Phase 1/2	130	2013-07-11	trimethoprim and sulfamethoxazole	A combination that names it	ClinicalTrials.gov
NCT01349192	Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)	Phase 2	47	2017-05-15	trimethoprim/sulfamethoxazole	A combination that names it	ClinicalTrials.gov
NCT01469637	Sulfamethoxazole Drug Interaction Study With MMX® Mesalazine/Mesalamine	Phase 1	44	2012-10-25	sulfamethoxazole	Its name	ClinicalTrials.gov

1 to 10 of 54

See all 54 trials

Comparisons in its trials29

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Trimethoprim-Sulfamethoxazole vs Placebo: Recurrent Febrile or Symptomatic Urinary Tract Infection During 2-year Follow-up	39 of 302	72 of 305	607	NCT00405704	Trial comparisons
Trimethoprim-Sulfamethoxazole vs Placebo: Treatment Failure Composite	14 of 302	27 of 305	607	NCT00405704	Trial comparisons
Trimethoprim-Sulfamethoxazole vs Placebo: serious adverse events	0 of 302	0 of 305	607	NCT00405704	Trial comparisons
Antimicrobial Therapy Plus Standard of Care vs Standard of Care: Number of Participants With Death From Any Cause	37 of 254	37 of 259	513	NCT02759120	Trial comparisons
Antimicrobial Therapy Plus Standard of Care vs Standard of Care: Number of Participants With First Non-elective, Respiratory Hospitalization or All-cause Mortality	52 of 254	56 of 259	513	NCT02759120	Trial comparisons
Antimicrobial Therapy Plus Standard of Care vs Standard of Care: deaths from any cause	37 of 254	37 of 259	513	NCT02759120	Trial comparisons
Antimicrobial Therapy Plus Standard of Care vs Standard of Care: Number of Participants With First Non-elective, Respiratory Hospitalization	36 of 254	31 of 259	513	NCT02759120	Trial comparisons
Antimicrobial Therapy Plus Standard of Care vs Standard of Care: Number of Participants With First Non-elective, All-cause Hospitalization	54 of 254	47 of 259	513	NCT02759120	Trial comparisons
Antimicrobial Therapy Plus Standard of Care vs Standard of Care: serious adverse events	71 of 254	65 of 259	513	NCT02759120	Trial comparisons
Cipro-susceptible vs Cipro-resistant: Number of Participants With Post-biopsy Infection.	6 of 430	3 of 80	510	NCT01659866	Trial comparisons

1 to 10 of 29

See all 29 comparisons in its trials

Papers from its trials62

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
29127863	RESULT	1	PubMed
27869362	RESULT	1	PubMed
25785967	RESULT	1	PubMed
24795142	RESULT	1	PubMed
24667978	RESULT	1	PubMed
23753091	RESULT	1	PubMed
23447696	RESULT	1	PubMed
23382157	RESULT	1	PubMed
23273022	RESULT	1	PubMed
23009139	RESULT	1	PubMed

1 to 10 of 62

See all 62 papers from its trials

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL443

GET https://conductscience.org/api/drugs/v1/CHEMBL443/diseases?page=2

API reference For AI assistants